Investigating Stem Cell Therapy in TBI and Other Conditions
Bijan Nejadnik, MD, chief medical officer, SanBio, also thanked neurological experts that collaborated on the phase 2 STEMTRA trial.
SB623 Stem Cell Therapy to Regain Motor Function in TBI
Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, discussed results of the phase 2 STEMTRA trial.
Brain Neurotherapy Bio Brings Clinical Programs for Parkinson and MSA to AskBio
Both therapeutic programs utilize AAD2-GDNF gene therapy targeted to brain structures vulnerable to Parkinson disease and multiple system atrophy.
SB623 Mesenchymal Stem Cell Implantation Efficacious and Well-Tolerated in TBI
There was no statistically significant difference between treatment-related adverse events in the SB623 stem cell and control groups.
SOD1 Variants Show Significant Association with ALS Risk
Researchers from the University of Turin also found that an NEFH variant showed a protective association with ALS.
Initial Results Prove Positive for Low-Dose AXO-AAV-GM1 in GM1 Gangliosidosis
These data follow a recent announcement from Sio Gene Therapies that the first patient in the high-dose cohort has been dosed.
